NCT03102229

Brief Summary

This study will aim to demonstrate that implementation of a rapid, multidisciplinary supportive care program for patients receiving chemoradiotherapy who are deemed to be at high risk for hospitalization based on real-time pedometer data will reduce the rate of hospitalization during chemoradiotherapy or within four weeks of radiotherapy completion.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2016

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2016

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

January 23, 2017

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2017

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 5, 2017

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2017

Completed
Last Updated

April 13, 2026

Status Verified

April 1, 2026

Enrollment Period

8 months

First QC Date

January 23, 2017

Last Update Submit

April 7, 2026

Conditions

Keywords

Activity MonitoringChemotherapyRadiotherapy

Outcome Measures

Primary Outcomes (1)

  • Number of patients hospitalized during treatment or within 4 weeks after completing radiotherapy.

    The primary endpoint of this study is hospitalization during chemoradiotherapy or within 4 weeks after completion of radiotherapy.

    During chemoradiotherapy or within 4 weeks after completion of radiotherapy.

Secondary Outcomes (7)

  • Activation of the enhanced supportive care protocol

    During chemoradiotherapy or within 4 weeks after completion of radiotherapy.

  • Frequency of clinician visits and supportive care measures implemented.

    During chemoradiotherapy or within 4 weeks after completion of radiotherapy

  • Patient-reported quality of life scores

    During chemoradiotherapy or within 4 weeks after completion of radiotherapy.

  • Treatment-related toxicities

    During chemoradiotherapy or within 4 weeks after completion of radiotherapy.

  • Disease status

    During chemoradiotherapy and up to two years after completion of radiotherapy.

  • +2 more secondary outcomes

Study Arms (1)

Activity Monitoring

EXPERIMENTAL

1. Enhanced Supportive Care - Status Checks Would occur everyday during treatment when a patient is deemed high-risk based on activity level. Other Names: •Daily Status Checks 2. Enhanced Supportive Care - Referrals On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor. Other Names: •Referrals

Other: Enhanced Supportive Care - Status ChecksOther: Enhanced Supportive Care - Referrals

Interventions

Would occur everyday during treatment when a patient is deemed high-risk.

Also known as: Daily Status Checks
Activity Monitoring

On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor.

Also known as: Referrals
Activity Monitoring

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \> 18
  • ECOG performance status 0-2
  • Able to ambulate independently (without the assistance of a cane or walker)
  • Diagnosis of invasive malignancy of the head and neck region, lung, esophagus, or stomach
  • Planned treatment with fractionated (≥15 treatments) external beam radiotherapy with concurrent chemotherapy (or cetuximab) with curative intent (including preoperative or postoperative treatment)
  • Women of childbearing potential must:
  • Have a negative serum or urine pregnancy test within 72 hours prior to the start of study therapy
  • Agree to utilize an adequate method of contraception throughout treatment and for at least 4 weeks after study therapy is completed
  • Be advised of the importance of avoiding pregnancy during trial participation and the potential risks of an unintentional pregnancy
  • All patients must sign study specific informed consent prior to study entry.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Montefiore Medical Center

The Bronx, New York, 10467, United States

Location

MeSH Terms

Conditions

Head and Neck NeoplasmsLung NeoplasmsEsophageal NeoplasmsStomach Neoplasms

Interventions

Referral and Consultation

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesGastrointestinal NeoplasmsDigestive System NeoplasmsDigestive System DiseasesEsophageal DiseasesGastrointestinal DiseasesStomach Diseases

Intervention Hierarchy (Ancestors)

Professional PracticeOrganization and AdministrationHealth Services Administration

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 23, 2017

First Posted

April 5, 2017

Study Start

July 1, 2016

Primary Completion

March 1, 2017

Study Completion

September 1, 2017

Last Updated

April 13, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations